Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AC Immune anti-tau drug semorinemab, developed in collaboration with Roche Genentech unit, failed its primary endpoint in the Phase 2 TAURIEL trial evaluating…
Genentech licensed rights to crenezumab in 2006, and in 2012 broadened the partnership to include semorinemab. The two deals had a combined value of more than…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Genentech (Roche) licensed AC Immune's anti-phospho-Tau immunotherapy program for Alzheimer's disease. AC Immune received upfront and near-term payments, with total potential value up to $570M in milestones plus royalties. The collaboration targets phosphorylated tau protein, a key pathological marker in Alzheimer's and other tauopathies.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / AC Immune SA (this deal) | 2012 | $570M | 41 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2012 deals · Roche Holding AG deals · Neurology deals